Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ChiCTR |
Last refreshed on:
|
12 April 2021 |
Main ID: |
ChiCTR2000040991 |
Date of registration:
|
2020-12-16 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study
|
Scientific title:
|
Cyclosporine A combined with eltrombopag in the treatment for primary immune thrombocytopenia: a prospective, multicenter, single-arm, open clinical study |
Date of first enrolment:
|
2022-03-02 |
Target sample size:
|
experimental group:28; |
Recruitment status: |
Recruiting |
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=65311 |
Study type:
|
Interventional study |
Study design:
|
Single arm
|
Phase:
|
4
|
|
Countries of recruitment
|
China
| | | | | | | |
Contacts
|
Name:
|
Jie Jin
|
Address:
|
79 Qingchun Road, Hangzhou, Zhejiang
310003
|
Telephone:
|
+86 13505716779 |
Email:
|
jiej0503@163.com |
Affiliation:
|
The First Affiliated Hospital, College of Medicine, Zhejiang University |
|
Name:
|
Chao Hu
|
Address:
|
79 Qingchun Road, Hangzhou, Zhejiang
310003
|
Telephone:
|
+86 13758188065 |
Email:
|
zjuhuchao@163.com |
Affiliation:
|
The First Affiliated Hospital, College of Medicine, Zhejiang University |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Aged 18~75 years;
2. Meet the diagnostic criteria of adult primary ITP;
3. Glucocorticoid therapy is ineffective, intolerant or recurring, and second-line treatment is required;
4. Platelet count < 20 x 10^9/L;
5. ECOG score <= 2;
6. Patients who are willing to receive treatment and sign an informed consent form.
Exclusion criteria: 1. Have a history of bone marrow stem cell abnormalities or observe other bone marrow abnormalities other than ITP-specific changes;
2. Combined with malignant tumors, active infections, other autoimmune diseases such as SLE, Sjogrens syndrome;
3. Received other ITP medications (including emergency treatment) within 2 weeks before the first administration (a stable dose of glucocorticoid, CsA, azathioprine, danazol, mycophenolate mofetil and other drugs before the first administration =4 Except for weeks);
4. Use Revolade (Eltrombopag) or Nplate (Romigrastim) or recombinant human thrombopoietin (rhTPO) or other c-Mpl (thrombopoietin receptor) stimulating drugs within 4 weeks before the first administration;
5. Received Decitabine within 4 weeks before the first dose;
6. Received splenectomy within 12 weeks before the first administration;
7. Received rituximab within six months before the first administration;
8. Have used the combination of CsA and Eltrombopag;
9. During the screening period, serum creatinine concentration> normal range, total bilirubin > 1.5 times the upper limit of normal range, alanine aminotransferase or aspartate aminotransferase> 3 times the upper limit of normal;
10. Have a history of blood clots or are using anticoagulant drugs;
11. Women during pregnancy and lactation;
12. Screening for hepatitis C antibodies, human immunodeficiency virus antibodies, or syphilis antibodies is positive;
13. Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive;
14. The researcher believes that it is not suitable for enrollment.
Age minimum:
18
Age maximum:
75
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
primary immune thrombocytopenia
|
Intervention(s)
|
experimental group:Cyclosporine A combined with eltrombopag;
|
Primary Outcome(s)
|
Overall response rate;
|
Secondary ID(s)
|
???(101)?
|
Source(s) of Monetary Support
|
self-raised
|
Ethics review
|
Status: Approved
Approval date: 23/09/2020
Contact:
??
Huili Zhou
+86 0571-611616
??
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|